Gracell Biotechnologies Inc. (GRCL) Financials

GRCL Assets vs Liabilities

DateAssetsLiabilities
Sept. 30, 2023 259.1 million 36.9 million
June 30, 2023 190.2 million 33.3 million
March 31, 2023 241.4 million 40.9 million
Dec. 31, 2022 240.4 million 40.7 million

GRCL Free Cash Flow and Stock based compensation

No data available :(

GRCL Net Income

No data available :(

GRCL Cash and Debt

Graph available only for paid members. Upgrade to see it.
DateCashDebtCapital Lease
Sept. 30, 2023 234.1 million - 1.7 million
June 30, 2023 164.0 million - 2.1 million
March 31, 2023 212.5 million - 2.7 million
Dec. 31, 2022 211.6 million - 3.5 million

GRCL Shares Outstanding

Graph available only for paid members. Upgrade to see it.
DateShares Outstanding
Sept. 30, 2023 11.5 million
June 30, 2023 9.4 million
March 31, 2023 9.9 million
Dec. 31, 2022 9.8 million

GRCL Expenses

Graph available only for paid members. Upgrade to see it.
DateCapexR&DG&AS&M
Sept. 30, 2023 - 12.3 million 4.3 million -
June 30, 2023 - 14.3 million 5.2 million -
March 31, 2023 - 16.5 million 5.3 million -
Dec. 31, 2022 - 16.4 million 5.3 million -

GRCL Cost of Revenue

Graph available only for paid members. Upgrade to see it.
DateRevenueCost of Revenue
Sept. 30, 2023 - -
June 30, 2023 - -
March 31, 2023 - -
Dec. 31, 2022 - -

GRCL

Price: $10.25

52 week price:
1.40
10.44

Earnings Per Share: -0.96 USD

P/E Ratio: -10.59

Exchange: NMS

Sector: Healthcare

Industry: Biotechnology

Country: China

Volume: 1.0 million

Market Capitalization: 989.9 million

Links: